- Home
- INSW vs ETNB Comparison
INSW vs ETNB Comparison
Compare INSW & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSW
- ETNB
- Stock Information
- Founded
- INSW 1999
- ETNB 2018
- Country
- INSW United States
- ETNB United States
- Employees
- INSW N/A
- ETNB N/A
- Industry
- INSW Semiconductors
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- INSW Technology
- ETNB Health Care
- Exchange
- INSW Nasdaq
- ETNB Nasdaq
- Market Cap
- INSW 1.8B
- ETNB 1.5B
- IPO Year
- INSW N/A
- ETNB 2019
- Fundamental
- Price
- INSW $41.01
- ETNB $9.53
- Analyst Decision
- INSW Buy
- ETNB Strong Buy
- Analyst Count
- INSW 2
- ETNB 8
- Target Price
- INSW $52.00
- ETNB $26.43
- AVG Volume (30 Days)
- INSW 517.1K
- ETNB 1.3M
- Earning Date
- INSW 08-06-2025
- ETNB 08-08-2025
- Dividend Yield
- INSW 9.73%
- ETNB N/A
- EPS Growth
- INSW N/A
- ETNB N/A
- EPS
- INSW 6.47
- ETNB N/A
- Revenue
- INSW $860,606,000.00
- ETNB N/A
- Revenue This Year
- INSW N/A
- ETNB N/A
- Revenue Next Year
- INSW $1.88
- ETNB N/A
- P/E Ratio
- INSW $6.36
- ETNB N/A
- Revenue Growth
- INSW N/A
- ETNB N/A
- 52 Week Low
- INSW $27.20
- ETNB $4.16
- 52 Week High
- INSW $56.66
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- INSW 59.51
- ETNB 42.40
- Support Level
- INSW $40.35
- ETNB $9.12
- Resistance Level
- INSW $40.89
- ETNB $10.48
- Average True Range (ATR)
- INSW 1.00
- ETNB 0.47
- MACD
- INSW 0.17
- ETNB -0.16
- Stochastic Oscillator
- INSW 74.22
- ETNB 17.90
About INSW International Seaways Inc.
International Seaways Inc owns and operates a fleet of oceangoing vessels engaged in the transportation of crude oil and petroleum products. The company's vessel operations are organized into two segments: Crude Tankers and Product Carriers. The fleet consists of ULCC, VLCC, Suezmax, Aframax, and Panamax crude tankers, as well as LR1, LR2, and MR product carriers.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).